Turning ideas into products

From idea to impact

UniQuest helps UQ researchers protect and commercialise their research. It has created more than 80 spin-out companies and is Australia’s leading university commercialising body, with a significant licensing portfolio which includes the Gardasil cervical cancer vaccine.

Since it began in 1984, UniQuest has licensed UQ technologies that have earned $US15.5 billion in gross product sales. Over the past 15 years, UniQuest has returned more than $435 million in revenue to The University of Queensland, much of which has been channelled back into research and intellectual property protection.

UniQuest in action

UniQuest Success Stories

When the research of Professor Ian Frazer and the late Dr Jian Zhou at The University of Queensland (UQ) led to a vaccine for the virus that causes 70 percent of all cervical cancer cases, they knew their work was going to be transformative. Since its release 10 years ago, the Gardasil® vaccine, which is designed to protect both women and men against the Human Papilloma Virus (HPV), has led to a 90 percent reduction in HPV infection rates in countries with high levels of immunisation.
Developed by Professor Matt Sanders and a team of researchers at the The University of Queensland’s Parenting and Family Support Centre (PFSC), the Triple P – Positive Parenting Program is a system of parenting support that can be tailored to fit different families’ needs.
With the help of UniQuest, Dendright negotiated and closed a research collaboration deal with Janssen Biotech, Inc. in 2012. In 2013, Janssen Biotech, Inc entered into a larger R&D collaboration with Dendright which included an option to license agreement for the rheumatoid arthritis immunotherapy.

Contact UniQuest

No matter what the industry problem or innovation challenge, we are committed to delivering high quality solutions, on time and to budget, that provide lasting beneficial impact. If you'd like to find out more about UniQuest, visit our website.